 Connection
Ping-Ching Hsu to Pyrimidines
This is a "connection" page, showing publications Ping-Ching Hsu has written about Pyrimidines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.207 |
|
|
|
-
Huang SH, Huang AC, Wang CC, Chang WC, Liu CY, Pavlidis S, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thorac Cancer. 2019 12; 10(12):2274-2281.
Score: 0.153
-
Chen CB, Wang CW, Lu CW, Chen WT, Zhou BR, Chu CY, Hsu SF, Yang CT, Wen-Cheng Chang J, Yang CK, Wang CL, Fang YF, Hsu PC, Hua CC, Wu CE, Ko HW, Chen KC, Yang YC, Tseng HC, Cheng AY, Tseng LC, Shih FY, Hung SI, Huang CY, Chung WH. Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity. J Allergy Clin Immunol Pract. 2025 Jan; 13(1):143-154.e10.
Score: 0.054
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|